WASHINGTON, March 28 (TNSrep) -- Northwestern University researchers have developed a medical device that integrates engineered drug-producing cells with bioelectronics to create a living pharmacy capable of treating chronic conditions inside the U.S. patient. Jonathan Rivnay, professor of biomedical engineering and materials science and engineering at Northwestern University, stated that the platform, known as HOBIT, allows for the steady delivery of multiple therapies simultaneously by keepin more PR

WASHINGTON, March 29 -- The Senate Commerce, Science and Transportation Committee released the following written testimony by Matthew Bergman, founding attorney at the Social Media Victims Law Center, from a March 18, 2026, hearing entitled "Liability or Deniability? Platform Power as Section 230 Turns 30": * * * Chairman Cruz and Ranking Member Cantwell, I am honored to appear before this Committee with these distinguished panelists to discuss the relationship between Section 230 of the Commu more PR

WASHINGTON, March 29 -- The Senate Commerce, Science and Transportation Committee released the following written testimony by Matthew Bergman, founding attorney at the Social Media Victims Law Center, from a March 18, 2026, hearing entitled "Liability or Deniability? Platform Power as Section 230 Turns 30": * * * (Continued from Part 1 of 3) Snap also used other forms of notifications to drive engagement. In 2023, Snap decided to implement an "always on badge" to get more users to try Spotlig more PR

EVANSTON, Illinois, March 28 -- The International Society for Stem Cell Research issued the following news release on March 27, 2026: * * * Stem Cell Reports Named Official Conference Journal for "Latest Advances in Stem Cell-Based Disease Modelling and Drug Screening" The meeting takes place in Copenhagen, Denmark, 23-24 April 2026 * The International Society for Stem Cell Research (ISSCR) announces that Stem Cell Reports, its official open-access, peer-reviewed journal published by Cell P more PR

NEW BRUNSWICK, New Jersey, March 28 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release: * * * STEMI DTU Randomized Control Trial Demonstrates for the First Time that a Combination of Delayed Reperfusion and Left Ventricular Unloading Does Not Increase Myocardial Infarct Size * NEW ORLEANS - Johnson & Johnson (NYSE: JNJ) - March 28, 2026 - Randomized controlled trial (RCT) data presented at the American College of Cardiology (ACC) 2026 today and simultaneo more PR